2-[4-(Trifluoromethoxy)anilino]-1,3-benzoxazin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2-[4-(Trifluoromethoxy)anilino]-1,3-benzoxazin-4-one
• 化学式: C₁₅H₉F₃N₂O₃
• 分子量: 322.24
• InChiKey: LLYBEHKZGCLPMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• EP2908843A1
  申请人：——

  公开号：EP2908843A1

  公开（公告）日：2015-08-26
• TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：EP2908843B1

  公开（公告）日：2019-09-04
• METHOD OF TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：US20150258175A1

  公开（公告）日：2015-09-17

  The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.
• US9889180B2
  申请人：——

  公开号：US9889180B2

  公开（公告）日：2018-02-13
• [EN] METHOD OF TREATING CANCER<br/>[FR] MÉTHODE DE TRAITEMENT DU CANCER
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2014077784A1

  公开（公告）日：2014-05-22

  The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.